	US 12,391,923 B2
	SIRPα-silenced natural killer (NK) cells
Tobias Deuse, Burlingame, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/621,689
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Jun. 24, 2020, PCT No. PCT/US2020/039220 § 371(c)(1), (2) Date Dec. 22, 2021, PCT Pub. No. WO2020/263880, PCT Pub. Date Dec. 30, 2020.
Claims priority of provisional application 62/866,683, filed on Jun. 26, 2019.
Prior Publication US 2022/0347215 A1, Nov. 3, 2022
Int. Cl. C12N 5/0783 (2010.01); A61K 40/15 (2025.01); A61K 40/42 (2025.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01)

CPC C12N 5/0646 (2013.01) [A61K 40/15 (2025.01); A61K 40/421 (2025.01); A61P 35/02 (2018.01); C07K 14/70503 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); C12N 2310/20 (2017.05); C12N 2500/32 (2013.01); C12N 2500/44 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/998 (2013.01); C12N 2506/45 (2013.01); C12N 2740/15042 (2013.01); C12N 2800/80 (2013.01)]

22 Claims

1. A population of modified Natural Killer (NK) cells, comprising a reduced Signal Regulatory Protein Alpha (SIRPα) function when compared to an NK cell population having an unmodified SIRPα function, wherein said modified NK cells effectively kill a population of cancer cells that express CD47 in an in vitro NK assay.